Soft Drink Supports Anti-cancer Drug

  • Author: ChemistryViews
  • Published: 27 October 2010
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Molecular Pharmaceutics/ACS
thumbnail image: Soft Drink Supports Anti-cancer Drug

Lilly Compound X (LCX) is an oncology drug that was tested in a phase I clinical study using starch blend capsules. The drug showed large inter- and intra-patient variability due to variations in stomach acidity and other factors.

Faraj Atassi and colleagues, Lilly Research Labs, Indianapolis, USA, conducted artificial stomach−duodenum (ASD) experiments to investigate the hypothesis that carefully selected dosing fluids would have an impact in minimizing exposure variability caused by the formulation.

Administrating Compound X with Captisol, a substance that helps improve the solubility of drug ingredients, along with Sprite was shown by the ADS to control stomach acidity in a way likely to allow optimal absorption of the drug into the body. Based on the results, the scientists suggest that patients in future clinical trials take the drug with Sprite.

Photo:  (C) PhotoDisc, Inc./Getty Images

Article Views: 2401

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from, please contact us first for permission. more

CONNECT: on Facebook on Twitter on YouTube on LinkedIn Sign up for our free newsletter

A product of ChemPubSoc Europe (16 European Chemical Societies)published by Wiley-VCH